Sandoz: Growth Hormone Biosimilar Efficacy Is Same As Forerunner
This article was originally published in PharmAsia News
Executive Summary
Sandoz Japan announced the approval of additional indications of Prader-Willi Syndrome short stature without epiphyseal line occlusion and SGA short stature for its growth hormone biosimilar Sandoz on Aug. 22, meaning the drug now has the same approved efficacy as its forerunner drug.